吉西他滨联合厄洛替尼在适合FOLFIRINOX的皮疹阳性转移性胰腺癌患者中的疗效
这项前瞻性II期研究纳入150例转移性胰腺导管腺癌患者,先接受4周吉西他滨联合厄洛替尼诱导治疗,根据皮疹出现情况决定后续治疗。皮疹阳性患者继续原方案,1年生存率达40.0%,中位总生存10.1个月。
要点
- 皮疹阳性患者继续吉西他滨联合厄洛替尼,1年生存率40.0%。
- 皮疹阴性患者转为FOLFIRINOX,1年生存率48.1%。
- 该方案在适合FOLFIRINOX的皮疹阳性患者中疗效与既往FOLFIRINOX报告相当。
核心结论
- 在适合FOLFIRINOX的皮疹阳性转移性胰腺癌患者中,一线吉西他滨联合厄洛替尼的1年生存率与既往FOLFIRINOX报告相当。
研究设计与样本
- 前瞻性II期研究,在20个中心招募150例转移性胰腺导管腺癌患者。
- 所有患者先接受4周吉西他滨联合厄洛替尼诱导治疗,随后根据皮疹发生情况决定后续治疗。
主要发现
- 转为FOLFIRINOX的皮疹阴性患者(n=27)1年生存率为48.1%(95%CI 28.7-68.1),中位总生存10.9个月,中位无进展生存6.6个月,总缓解率33.3%。
- 皮疹阴性患者基线生活质量较低,但在FOLFIRINOX期间似乎疼痛控制改善。
临床怎么用
- 对于适合FOLFIRINOX的转移性胰腺癌患者,可先给予吉西他滨联合厄洛替尼诱导治疗,根据皮疹出现情况选择后续方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In metastatic pancreatic ductal adenocarcinoma (mPDAC) treatment, erlotinib is known to be more effective in patients developing skin rash. Treatment with the FOLFIRINOX regimen is only performed in fit patients following defined inclusion criteria. The present study investigates the efficacy of gemcitabine plus erlotinib (gem/erlotinib) in rash-positive patients fit for FOLFIRINOX. PATIENTS AND METHODS: For this prospective phase II study, 150 patients were recruited in 20 centres. All patients received gem/erlotinib for 4 weeks (run-in phase); the subsequent treatment was determined by the development of skin rash: patients with rash grades 1-4 continued with gem/erlotinib, rash-negative patients were switched to FOLFIRINOX. Primary study end-point was to achieve a 1-year survival rate in rash-positive patients ≥40%. RESULTS: Ninety patients were deemed positive for skin rash by the end of the run-in phase, showing a 1-year survival rate of 40.0% (95% confidence interval [CI] 29.8-50.9). Median overall survival (OS) was 10.1 months, progression-free survival (PFS) was 3.8 months and overall response rate (ORR) was 23.3%. Patients switched to FOLFIRINOX (n = 27) had a 1-year survival rate of 48.1% (95% CI 28.7-68.1), a median OS of 10.9 months, a median PFS of 6.6 months and an ORR of 33.3%. Rash-negative patients had a lower quality of life at baseline but seemed to experience an improved control of pain during FOLFIRINOX. CONCLUSIONS: First-line treatment with gem/erlotinib was effective in fit, rash-positive mPDAC patients achieving a 1-year survival rate comparable to previous reports for FOLFIRINOX. The study was registered at clinicaltrials.gov (NCT0172948) and Eudra-CT (2011-005471-17).
引用
- Haas M, Siveke JT, Schenk M, et al. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'. Eur J Cancer. 2018. PMID: 29549862. doi:10.1016/j.ejca.2018.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。